FDA Alert for Darbepoetin alfa


The FDA has issued an alert about the use of darbepoetin alfa (Aranesp), an ery-thropoiesis-stimulating agent (ESA), to treat anemia in cancer patients who are not receiving chemotherapy. In a large clinical trial, patients randomly received either the approved dosing regimen of darbepoetin alfa or placebo. The treated patients had a higher death rate and no reduction in the need for transfusions, compared with placebo patients.
canadian antibiotics

ESAs are not approved by the FDA to treat anemia in cancer patients not receiving chemotherapy.